School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab-144411, India.
Chitkara College of Pharmacy, Chitkara University, Punjab-140401, India.
Curr Neuropharmacol. 2021;19(7):957-989. doi: 10.2174/1570159X18666201109090824.
Huntington's disease (HD) is an autosomal fatal genetic disease in which degeneration of neuronal cells occurs in the central nervous system (CNS). Commonly used therapeutics are cludemonoamine depletors, antipsychotics, antidepressants, and tranquilizers. However, these drugs cannot prevent the psychotic, cognitive, and behavioral dysfunctions associated with HD. In addition to this, their chronic use is limited by their long-term side effects. Herbal drugs offer a plausible alternative to this and have shown substantial therapeutic effects against HD. Moreover, their safety profile is better in terms of side effects. However, due to limited drug solubility and permeability to reach the target site, herbal drugs have not been able to reach the stage of clinical exploration. In recent years, the paradigm of research has been shifted towards the development of herbal drugs based nanoformulations that can enhance their bioavailability and blood-brain barrier permeability. The present review covers the pathophysiology of HD, available biomarkers, phytomedicines explored against HD, ongoing clinical trials on herbal drugs exclusively for treating HD and their nanocarriers, along with their potential neuroprotective effects.
亨廷顿病(HD)是一种常染色体致命性遗传疾病,其中枢神经系统(CNS)中的神经元细胞发生退化。常用的治疗药物有单胺耗竭剂、抗精神病药、抗抑郁药和镇静剂。然而,这些药物不能预防与 HD 相关的精神、认知和行为功能障碍。此外,由于其长期的副作用,它们的慢性使用受到限制。草药药物提供了一种合理的替代方法,并显示出对 HD 的显著治疗效果。此外,它们在副作用方面的安全性更高。然而,由于草药药物的溶解度和对靶部位的通透性有限,因此尚未能够达到临床探索阶段。近年来,研究范式已经转向开发基于草药的纳米制剂,以提高其生物利用度和血脑屏障通透性。本综述涵盖了 HD 的病理生理学、可用的生物标志物、针对 HD 探索的植物药、专门用于治疗 HD 的草药药物的临床试验及其纳米载体,以及它们的潜在神经保护作用。